Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gregory Zuckerman: A shot to save the world: the inside story of the life-or-death race for a COVID-19 vaccine

Gregory Zuckerman: A shot to save the world: the inside story of the life-or-death race for a... Business Economics (2022) 57:222–224 https://doi.org/10.1057/s11369-022-00269-0 BOOK RE VIE W Gregory Zuckerman: A shot to save the world: the inside story of the life‑or‑death race for a COVID‑19 vaccine Portfolio/Penguin, 2021 Catherine L. Troisi Published online: 25 June 2022 © National Association for Business Economics 2022 In December 2019, infections with a previously unknown platforms; that is, the type of technology used to manufac- virus were reported from Wuhan, China. By March, this ture vaccines, in licensed vaccines in the United States. The virus, subsequently named SARS-CoV-2, had spread around oldest method is to take a virus or bacteria and inactivate it, the world. Initial preventive measures were limited to non- so that it cannot cause an infection. One type of influenza pharmaceutical interventions; masking, social distancing, vaccine is an example, as is the hepatitis A vaccine. Some and environmental hygiene. Although public health profes- vaccines use just part of the virus or bacteria—for example, sionals knew a targeted vaccine would be needed to stop those against the human papillomavirus (HPV) or pertus- transmission of the virus, many scientists were convinced sis. We also have vaccines that use an attenuated, or weak- that it could be years until a safe effective vaccine was pro- ened, virus, precluding the virus from causing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Business Economics Springer Journals

Gregory Zuckerman: A shot to save the world: the inside story of the life-or-death race for a COVID-19 vaccine

Troisi, Catherine L.
Business Economics , Volume 57 (4) – Oct 1, 2022
Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/gregory-zuckerman-a-shot-to-save-the-world-the-inside-story-of-the-dbQRatHoi9

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © National Association for Business Economics 2022
ISSN
0007-666X
eISSN
1554-432X
DOI
10.1057/s11369-022-00269-0
Publisher site
See Article on Publisher Site

Abstract

Business Economics (2022) 57:222–224 https://doi.org/10.1057/s11369-022-00269-0 BOOK RE VIE W Gregory Zuckerman: A shot to save the world: the inside story of the life‑or‑death race for a COVID‑19 vaccine Portfolio/Penguin, 2021 Catherine L. Troisi Published online: 25 June 2022 © National Association for Business Economics 2022 In December 2019, infections with a previously unknown platforms; that is, the type of technology used to manufac- virus were reported from Wuhan, China. By March, this ture vaccines, in licensed vaccines in the United States. The virus, subsequently named SARS-CoV-2, had spread around oldest method is to take a virus or bacteria and inactivate it, the world. Initial preventive measures were limited to non- so that it cannot cause an infection. One type of influenza pharmaceutical interventions; masking, social distancing, vaccine is an example, as is the hepatitis A vaccine. Some and environmental hygiene. Although public health profes- vaccines use just part of the virus or bacteria—for example, sionals knew a targeted vaccine would be needed to stop those against the human papillomavirus (HPV) or pertus- transmission of the virus, many scientists were convinced sis. We also have vaccines that use an attenuated, or weak- that it could be years until a safe effective vaccine was pro- ened, virus, precluding the virus from causing

Journal

Business Economics – Springer Journals

Published: Oct 1, 2022

There are no references for this article.